Iodine-131-Lipiodol therapy in hepatic tumours
| Autor: | Hans Jürgen Biersack, Amir Sabet, Jörn Risse, Hojjat Ahmadzadehfar, Kai Wilhelm |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Carcinoma Hepatocellular medicine.medical_treatment Gastroenterology General Biochemistry Genetics and Molecular Biology Iodine Radioisotopes Ethiodized Oil Internal medicine medicine Animals Humans Molecular Biology Contraindication business.industry Incidence (epidemiology) Liver Neoplasms Cancer medicine.disease digestive system diseases Portal vein thrombosis Hepatocellular carcinoma Lipiodol Liver cancer business Adjuvant medicine.drug |
| Zdroj: | Methods. 55:246-252 |
| ISSN: | 1046-2023 |
| DOI: | 10.1016/j.ymeth.2011.05.003 |
| Popis: | The incidence of hepatocellular carcinoma (HCC) is worldwide sharply on the rise and patients with advanced disease carry a poor prognosis. HCC is the sixth most common cancer and the third leading cause of cancer associated deaths in the world. Intra-arterially administered 131 I-Lipiodol is selectively retained by hepatocellular carcinomas, and has been used as a vehicle for delivery of therapeutic agents to these tumours. In this review we focus on the therapeutic indications, usefulness and methods of treatment with 131-Iodine Lipiodol. The effectiveness of 131 I-Lipiodol treatment is proven both in the treatment of HCC with portal thrombosis and also as an adjuvant to surgery after the resection of HCCs. It is at least as effective as chemoembolization and is tolerated much better. Severe liver dysfunction represents theoretic contraindication for radioembolization as well as for TACE. In such cases 131 I-Lipiodol is an alternative therapy option especially in tumours smaller than 6 cm. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect